VRTX — VERTEX PHARMACEUTICALS

Ownership history in Elefante Mark B  ·  5 quarters on record

This page tracks every 13F SEC filing in which Elefante Mark B reported a position in VERTEX PHARMACEUTICALS (VRTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
2.17% (2025 Q1)
Avg. % of fund
1.88%
First filed
2024 Q4
Last filed
2025 Q4
Quarters held
5
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 7,015 +352 +5.3% 1.95% $3.2M $453.36
2025 Q3 ADDED 6,663 +831 +14.2% 1.67% $2.6M $391.64
2025 Q2 ADDED 5,832 +171 +3.0% 1.95% $2.6M $445.20
2025 Q1 ADDED 5,661 +1,109 +24.4% 2.17% $2.7M $484.82
1 older quarter hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    VRTX price (monthly, adj. close)

Other funds also holding VRTX

As of 2025 Q4 — sorted by position size

Provident Investment Management, Inc. 3Y 7Y 6.16% Bellevue Group AG 3Y 7Y 5.85% Andrew Hill Investment Advisors, Inc. 3Y 4.28% Iron Triangle Partners LP 3Y 3.99% Atle Fund Management AB 3Y 7Y 3.32% MCRAE CAPITAL MANAGEMENT INC 3Y 7Y 3.29% Sofinnova Investments, Inc. 3Y 7Y 3.22% SECTORAL ASSET MANAGEMENT INC 3Y 7Y 2.91% Birch Hill Investment Advisors LLC 3Y 7Y 2.89% NIA IMPACT ADVISORS, LLC 3Y 2.68%
← Back to Elefante Mark B Holdings